Getinge Interim Report July - September 2023: Higher sales, gradually strengthened margins and stable cash flows
“Getinge’s sales rose organically by 5.7% in the quarter,” says Mattias Perjos, President & CEO at Getinge. “Most of the operations in Acute Care Therapies performed positively. Sales in Life Science were unchanged and Surgical Workflows grew in all product categories and regions. The order intake declined organically by a total of 1.9% in the quarter, which was exclusively linked to Acute Care Therapies.”The Group’s margins and cash flow were positively impacted sequentially by higher deliveries of consumables, mainly in Cardiac Assist. However, continuing low demand in products for the